Our conversations with private company executives aid our understanding of emerging trends in the diagnostics sector. For this spotlight, we interviewed LightDeck CEO Nick Traggis to better understand the company’s highly differentiated diagnostic platform that provides results at the point of care.
The LightDeck platform is built on advanced planar waveguide technology, a highly sensitive imaging system providing quantitative, on-the-spot diagnostic test results within minutes. This unique testing platform is composed of inexpensive, disposable test cartridges and a portable analyzer making testing practical wherever and whenever needed. LightDeck is introducing a portfolio of in vitro diagnostic panels. The first is an ultra-rapid five-minute antigen test for COVID-19, scheduled for launch in the first quarter of 2022. The company has raised over $115 million to date including over $75 million in nondilutive government funding.
Click the article title above or go to the following link for the full report: https://williamblair.bluematrix.com/sellside/EmailDocViewer?encrypt=47b5e87d-2293-48ba-9cd3-4d3e766bbfe3&mime=pdf&co=williamblair&id=nick.traggis@lightdeckdx.com&source=mail